|
Sign In to gain access to subscriptions and/or personal tools.
|
Pharmacist-led structured care for patients with diabetic nephropathy
Christopher JG Kelly
Diabetes Unit, Stirling Royal Infirmary, Livilands, Stirling, UK, chriskelly{at}nhs.net
Gillian Booth
Diabetes Unit, Stirling Royal Infirmary, Livilands, Stirling, UK
Intensive multifactorial intervention reduces end points in patients with diabetic nephropathy. Traditional clinics struggle to provide the intensity of care required to meet targets for this growing patient group. We designed a pharmacist-led, protocol driven clinic to offer stepwise intensive treatment to patients with diabetic nephropathy picked up at the traditional secondary care clinic. One hundred and sixteen individuals received more than one review. The clinic achieved significant improvements in blood pressure (BP): systolic 151±19 mmHg vs.133±15 mmHg (p<0.001), diastolic 80±10 mmHg vs. 68±10 mmHg (p<0.001) and total cholesterol 4.56 mmol/L±1.05 mmol/L vs. 4.03±1.07 mmol/L (p<0.001). Albumin:creatinine ratio also improved 27±44 vs. 20±31 (p=0.02). Structured intervention within a pharmacist-led clinic has led to a rapid and significant reduction in BP and cholesterol in microalbuminuric patients. This format of care can form the basis of patient focused, target driven, care.
Key Words: diabetic nephropathy • healthcare delivery • pharmacist • structured care.
References
- Ritz E., Orth SR Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33.[Free Full Text]
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk Nof macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]
- Fried L., Orchard T., Kasiske B., for the Lipids and Renal Disease Progression Meta-analysis Study Group. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney International 2001;59:260-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Parving HH, Lehnert H., Brochner-Mortensen J. et al. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
- Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
- Gaede P., Vedel P., Larsen N., Jensen GVH, Parving HH, Pedersen O. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003;348:383-93.[Abstract/Free Full Text]
- Joss N., Ferguson C., Brown C., Deighan CJ, Paterson KR, Boulton-Jones JM Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 2004;97:219-27.[Abstract/Free Full Text]
- Joss N., Paterson KR, Deighan CJ, Simpson K., Boulton-Jones JM Diabetic nephropathy: how effective is treatment in clinical practice? QJM 2002;95:41-9.[Abstract/Free Full Text]
- Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes 2001;20-23
- Williams B., Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40.[Free Full Text]
- Leung WY, So WY, Tony PC et al. Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy. Am J Med 2005;118:1414.e21-1414.e27.
The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 2,
86-88 (2008)
DOI: 10.1177/14746514080080020601
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. A Mugarza, J. P Wilding, A. Woodward, K. Hayden, and G. V Gill
Achieving blood pressure control in patients with type 2 diabetes and diabetic renal disease by a nurse-led protocol based clinic
The British Journal of Diabetes & Vascular Disease,
November 1, 2008;
8(6):
279 - 284.
[Abstract]
[PDF]
|
|
|
|
|
